Literature DB >> 18532997

The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects.

K Umemura, T Furuta, K Kondo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18532997     DOI： 10.1111/j.1538-7836.2008.03050.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  53 in total

1.  Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes.

Authors:  Takahisa Furuta; Takayuki Iwaki; Kazuo Umemura
Journal:  Br J Clin Pharmacol       Date:  2010-09       Impact factor: 4.335

2.  Genetic CYP2C19 polymorphism dependent non-responders to clopidogrel therapy--does structural design, dosing and induction strategies have a role to play?

Authors:  Nuggehally R Srinivas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2009 Jul-Sep       Impact factor: 2.441

3.  Different Clopidogrel Response Elicited by Lansoprazole or Esomeprazole in Patients Undergoing Neurointervention with Dual Antiplatelet Therapy.

Authors:  Kouhei Nii; Yusuke Morinaga; Takafumi Mitsutake; Ritsurou Inoue; Toshio Higashi
Journal:  Clin Drug Investig       Date:  2019-10       Impact factor: 2.859

4.  Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.

Authors:  Jessica L Mega; Tabassome Simon; Jean-Philippe Collet; Jeffrey L Anderson; Elliott M Antman; Kevin Bliden; Christopher P Cannon; Nicolas Danchin; Betti Giusti; Paul Gurbel; Benjamin D Horne; Jean-Sebastian Hulot; Adnan Kastrati; Gilles Montalescot; Franz-Josef Neumann; Lei Shen; Dirk Sibbing; P Gabriel Steg; Dietmar Trenk; Stephen D Wiviott; Marc S Sabatine
Journal:  JAMA       Date:  2010-10-27       Impact factor: 56.272

Review 5.  Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC).

Authors:  Thomas O Bergmeijer; Jean-Luc Reny; Ruth E Pakyz; Li Gong; Joshua P Lewis; Eun-Young Kim; Daniel Aradi; Israel Fernandez-Cadenas; Richard B Horenstein; Ming Ta Michael Lee; Ryan M Whaley; Joan Montaner; Gian Franco Gensini; John H Cleator; Kiyuk Chang; Lene Holmvang; Willibald Hochholzer; Dan M Roden; Stefan Winter; Russ B Altman; Dimitrios Alexopoulos; Ho-Sook Kim; Jean-Pierre Déry; Meinrad Gawaz; Kevin Bliden; Marco Valgimigli; Rossella Marcucci; Gianluca Campo; Elke Schaeffeler; Nadia P Dridi; Ming-Shien Wen; Jae Gook Shin; Tabassome Simon; Pierre Fontana; Betti Giusti; Tobias Geisler; Michiaki Kubo; Dietmar Trenk; Jolanta M Siller-Matula; Jurriën M Ten Berg; Paul A Gurbel; Jean-Sebastien Hulot; Braxton D Mitchell; Matthias Schwab; Marylyn DeRiggi Ritchie; Teri E Klein; Alan R Shuldiner
Journal:  Am Heart J       Date:  2017-12-17       Impact factor: 4.749

Review 6.  The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19.

Authors:  Yao Yang; Joshua P Lewis; Jean-Sébastien Hulot; Stuart A Scott
Journal:  Expert Opin Drug Metab Toxicol       Date:  2015-07-14       Impact factor: 4.481

7.  Influence of Genetic Polymorphisms on Clopidogrel Response and Clinical Outcomes in Patients with Acute Ischemic Stroke CYP2C19 Genotype on Clopidogrel Response.

Authors:  Yan Han; Hui-Hui Lv; Xu Liu; Qiang Dong; Xiao-Li Yang; Shi-Xu Li; Shuai Wu; Jian-Ming Jiang; Zheng Luo; De-Sheng Zhu; Yi Zhang; Yi Zheng; Yang-Tai Guan; Jian-Feng Xu
Journal:  CNS Neurosci Ther       Date:  2015-07-15       Impact factor: 5.243

8.  [13C]pantoprazole breath test as a predictor of the anti-platelet function of clopidogrel.

Authors:  Takahisa Furuta; Takayuki Iwaki; Kazuo Umemura
Journal:  Eur J Clin Pharmacol       Date:  2010-03-27       Impact factor: 2.953

9.  Genetic testing for CYP450 polymorphisms to predict response to clopidogrel: current evidence and test availability. Application: pharmacogenomics.

Authors:  Renée M Ned Mmsc Phd
Journal:  PLoS Curr       Date:  2010-09-20

10.  Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.

Authors:  Christoph Varenhorst; Stefan James; David Erlinge; John T Brandt; Oscar O Braun; Michael Man; Agneta Siegbahn; Joseph Walker; Lars Wallentin; Kenneth J Winters; Sandra L Close
Journal:  Eur Heart J       Date:  2009-05-09       Impact factor: 29.983
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.